Viloxazine was marketed as an antidepressant in Europe for more than 2 decades under an immediate-release formulation before its potential as a treatment for patients with attention-deficit hyperactivity disorder (ADHD) was considered. Viloxazine received its first endorsement in the United Kingdom in 1971 and was subsequently recognized as an antidepressant in several other nations. However, commercial reasons led to its discontinuation in 2002.
